Stereotaxis, Inc. (STXS) reported its fourth‑quarter and full‑year 2025 financial results on March 9 2026, showing total revenue of $32.4 million—an increase of 20% from $26.9 million in 2024. System revenue rose 18% to $10.2 million, while recurring revenue grew 21% to $22.2 million, driven by early sales of the GenesisX robot and MAGiC ablation and mapping catheters. Gross margin for the year was 53% of revenue, with recurring revenue margins at 67% and system margins at 21%. Operating loss improved to $9.3 million from $12.4 million in 2024, reflecting lower one‑time charges and a stronger mix of higher‑margin recurring products. Earnings per share were –$0.06, matching the consensus estimate of –$0.06 and indicating that cost control and a favorable product mix offset the continued operating loss.
The fourth‑quarter revenue totaled $8.6 million, up 36% from $6.3 million in the prior year’s fourth quarter. Q4 recurring revenue was $5.3 million and system revenue was $3.3 million. While the quarter’s revenue missed analyst estimates of $9.15 million to $9.26 million, the EPS met expectations, suggesting that the company’s cost structure and pricing power helped neutralize the revenue shortfall. The miss was largely attributed to manufacturing ramp challenges for GenesisX and MAGiC, which limited commercial deliveries during the quarter.
Gross margin remained strong at 53% of revenue, but recurring revenue margins were slightly compressed by acquisition‑related accounting and lower initial margins on new devices. System margins were constrained by fixed overhead spread over low production levels. Despite these headwinds, the company’s recurring revenue mix—now $22.2 million versus $18.3 million a year earlier—demonstrates a shift toward higher‑margin, subscription‑style products that should improve profitability as volumes grow.
"The past year saw tremendous progress with significant regulatory approvals globally, advancement of a broad pipeline of innovations, and revenue growth of over 20%. I’m proud of what our team has accomplished and excited for the year ahead," said Chairman and CEO David Fischel. "The highlight of the past year was achieving regulatory approvals in the United States and Europe for the GenesisX robot, MAGiC ablation catheter, and MAGiC Sweep high‑density mapping catheter. This core product portfolio serves as a foundation for significant commercial growth as the only robotic technology in the attractive electrophysiology market," he added. CFO Kimberly Peery noted, "Revenue for the fourth quarter of 2025 totaled $8.6 million, a 36% increase compared to $6.3 million in the prior year fourth quarter." She also highlighted, "Full year recurring revenue of $22.2 million compared to $18.3 million in the prior year, with growth driven by increased catheter revenue."
Management reiterated 2026 guidance, forecasting double‑digit revenue growth and a total revenue target exceeding $40 million. The company emphasized continued ramp‑up of GenesisX and MAGiC production, noting that the first commercial GenesisX system was installed in Europe earlier in the year. The guidance signals confidence in the company’s ability to scale its high‑margin recurring business while navigating manufacturing challenges. Investors will likely view the revenue miss as a short‑term operational hurdle, but the strong recurring revenue growth, improved operating loss, and regulatory approvals suggest a positive trajectory toward profitability.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.